medigraphic.com
ISSN 0016-3813 (Print)

2014, Number 4

<< Back Next >>

Gac Med Mex 2014; 150 (4)

Prevalencia del síndrome metabólico (SM) en pacientes con psoriasis

Espinoza HCJ, Lacy NRM, Soto LME, Kresch TNS, Vega-Memije ME

Language: Spanish
References: 25
Page: 311-316
PDF size: 86.41 Kb.


ABSTRACT

Background: Psoriasis is a chronic inflammatory disease associated with increased cardiovascular risk. Metabolic syndrome (MS) is a significant predictor of cardiovascular events. Objective: To assess the prevalence of MS in a Mexican population with psoriasis. Methods: A descriptive, case control study was performed, involving a series of 209 patients. Relevant demographic, clinical, anthropometric, and analytic information was obtained from all participants. Metabolic syndrome was diagnosed according to the NCEP-ATPIII criteria. Results: The study included 103 patients with psoriasis and 106 controls. The mean age of the case patients was 48.37 years; 55% were women and 46% were men. Metabolic syndrome was significantly more common in psoriatic patients than in controls (41.7 vs. 20%, odds ratio: 1.738; 95% CI: 1.194-2.531; p ‹ 0.001). We also found a higher frequency of diabetes mellitus (17.3 vs. 6.6%; p = 0.001), alcoholic habits (8.7 vs. 0.9%; p = 0.009), and higher levels of blood pressure (p = 0.002), BMI (p = 0.016), waist circumference (p = 0.008), and triglycerides (p = 0.002).Conclusions: Psoriatic patients have a higher prevalence of metabolic syndrome, which can favor cardiovascular events.


REFERENCES

  1. Gelfand JM, Weinstein R, Porter SB, Neimman AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537-41.

  2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rosltad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-9.

  3. Neimann AL, Porter S, Gelfand JM. Epidemiology of psoriasis. Expert Rev Dermatol. 2006;1:63-75.

  4. Tirado A. Psoriasis. En: Saúl CA, Arellano I, Peniche A, eds. Lecciones de Dermatología de Saúl. 14.a ed. México, D.F.: Méndez Editores; 2011. p. 495-510.

  5. Schon MP, Boehncke WH. Psoriasis. N Eng J Med. 2005;352:1899-912.

  6. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:94-100.

  7. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-60.

  8. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.

  9. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347-54.

  10. Hensler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;2(6):982-6.

  11. Shaphiro J, Cohen A, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56:629-34.

  12. Javidi Z, Tayyebi N, Nahidi Y. Serum lipid Abnormalities and Psoriasis. J Eur Acad Dermatol. 2007;52:89-92.

  13. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Med. 2007;157:68-73.

  14. Gelfand JM, Niemman AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of Myocardial Infarction in Patients with Psoriasis. JAMA. 2006;296:1735-41.

  15. Zhao YF, Feng DD, Chen C. Contribution of adipocyte-derived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol. 2006;38: 804-19.

  16. Ludwing R, Herzog C, Rostock A. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271-6.

  17. Puig L. La psoriasis, ¿una enfermedad sistémica? Actas Dermosifiliogr. 2007;98:396-402.

  18. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.

  19. Trevisan M. Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: A population-based study. Am J Epidemiol. 1998;148:958-66.

  20. Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159:10-7.

  21. Hotamisligil GS, Budavari A, Murray D. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994;94:1543-9.

  22. González-Chávez A, Simental L, Elizondo-Argueta S, Sánchez ZJ, Gutiérrez SG, Guerrero-Romero F. Prevalencia de síndrome metabólico entre adultos mexicanos no diabéticos, usando las definiciones de la OMS, NCEP-ATPIII e IDF. Rev Med Hosp Gen Mex. 2008;71(1):11-9.

  23. Assman G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond). 2008;32:S11-6.

  24. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654-62.

  25. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol. 1999;41:401-7.




2020     |     www.medigraphic.com